581301-U

Ascentis^® C18 (3 µm) HPLC Columns

L × I.D. 10 cm × 2.1 mm, HPLC Column

• Synonym(e): Ascentis RP18 HPLC Column
• UNSPSC-Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Eigenschaften

• product name: Ascentis^® C18 HPLC-Säule, 3 μm particle size, L × I.D. 10 cm × 2.1 mm
• Materialien: stainless steel column
• Qualitätsniveau: 100
• Agentur: suitable for USP L1 (Similar to Phenomenex Luna C18)
• Produktlinie: Ascentis^®
• Leistungsmerkmale: endcapped
• Hersteller/Markenname: Ascentis^®
• Verpackung: 1 ea of
• Kennzeichnungsgrad: 25% Carbon loading
• Parameter: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• Methode(n): HPLC: suitable; LC/MS: suitable
• L × ID: 10 cm × 2.1 mm
• Oberflächenbereich: 450 m²/g
• Oberflächendeckung: 3.7 μmol/m²
• Verunreinigungen: <5 ppm metals
• Matrix: fully porous particle; silica gel high purity, spherical
• Aktive Matrixgruppe: C18 (octadecyl) phase
• Partikelgröße: 3 μm
• Porengröße: 100 Å
• operating pH range: 2-8
• Anwendung(en): food and beverages
• Trenntechnik: reversed phase

Beschreibung

Allgemeine Beschreibung

Die Ascentis C18 ist eine äußerst stabile und zuverlässige HPLC-Säule, die eine symmetrische Peak-Form sowie eine ausgezeichnete Retention auch schwieriger Verbindungen ermöglicht.

Anwendung

• Identification of recombinant human insulin and biosynthetic insulin analogues by multiplexed targeted unlabeled mass spectrometry of proteotypic tryptic peptides.: This study employs the Ascentis^® C18 HPLC column for the separation of proteotypic tryptic peptides, allowing the identification of human insulin and biosynthetic insulin analogues through multiplexed targeted unlabeled mass spectrometry. The method demonstrated high specificity and sensitivity, enhancing the accuracy of insulin analysis in pharmaceutical research (Qasem et al., 2019).


• Development and validation of a novel stability-indicating HPLC method for the simultaneous assay of betamethasone-17-valerate, fusidic acid, potassium sorbate, methylparaben, and propylparaben in a topical cream preparation.: Utilizing the Ascentis^® C18 HPLC column, this research presents a novel stability-indicating method for the simultaneous assay of multiple compounds in a topical cream. The validated method offers robust stability assessment, critical for ensuring the quality and efficacy of pharmaceutical formulations (Byrne et al., 2014).


• HPLC-DAD and HPLC-ESI-MS/MS methods for metabolite profiling of propolis extracts.: This paper describes the use of the Ascentis^® C18 HPLC column in HPLC-DAD and HPLC-ESI-MS/MS methods to profile metabolites in propolis extracts. The column′s performance in separating complex mixtures highlights its utility in natural product research and quality control (Pellati et al., 2011).


• Practical comparison of 2.7 microm fused-core silica particles and porous sub-2 microm particles for fast separations in pharmaceutical process development.: This study compares the performance of the Ascentis^® C18 HPLC column with other chromatographic columns for fast separations in pharmaceutical process development. The Ascentis^® column provided superior separation efficiency and speed, making it advantageous for high-throughput pharmaceutical analysis (Abrahim et al., 2010).

Leistungsmerkmale und Vorteile

• Ausgezeichnete Retention
• Symmetrische Peak-Form
• Hohe Reproduzierbarkeit
• Vollständig LC-MS-kompatibel

Empfohlene Produkte

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Rechtliche Hinweise

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable